Cookies on this site

In a research letter to the British Journal of Surgery (BJS) a team of plastic surgeons reveal the effect of the COVID-19 pandemic on skin cancer surgery in the UK.

A doctor looks at the moles on someone's back

Abhilash Jain, Associate Professor of Plastic and Hand Surgery at NDORMS, was the senior author that conducted a multi-centre, prospective cohort study and survey of Plastic Surgeons. 

A national audit of skin cancer excisions by Plastic Surgeons was carried out throughout lockdown (March 16 – June 14 2020), and compared to a control - data collected immediately prior to lockdown (March 16 – 22 ) while normal NHS activities were still being undertaken. Data on 2050 patients from 32 Plastic Surgery units were included, as well as consecutive monthly surveys of Plastic Surgeons from 34 units to confirm trends. 

The study found that all skin cancer treatment was negatively affected by the pandemic:

  • The median number of general anaesthetic (GA) lists per week per institution fell from 3 pre-lockdown to 0⋅5 in April
  • Local anaesthetic (LA) lists were reduced in April and May but recovered in June.
  • The number of non-melanoma skin cancer’s (NMSC) treated per week fell by 27-47% throughout April
  • Excision of Squamous cell carcinomas (71%) was prioritised over basal cell carcinomas (28%) 

Abhilash said: “Overall we saw a lower number of surgeries for tumours taking place. At the same time there was a reduction in Moh’s surgery, radiotherapy services and fewer patients being offered immunotherapy. Long term the risk of untreated skin cancer may now be considered greater than COVID-19 and we would urge that all cancer services be resumed urgently.”

 

Similar stories

Could patients with common fractures recover without routine hospital follow-up?

The FASTER study will investigate whether thousands of people with common fractures can recover just as well with good-quality advice and rehabilitation guidance, without the need for routine hospital follow-up appointments.

Could the gut’s nervous system hold new clues to treating Crohn’s disease?

Researchers at the Kennedy Institute are investigating whether the nervous system within the gut could provide a new way to understand and ultimately treat Crohn’s disease.

NDORMS appoints a new Research Professor of Regulatory Innovation to help accelerate the development pipeline of new treatments

Lincoln Tsang has been appointed as the new John Climax Research Professor of Regulatory Innovation – a new role at NDORMS and the University of Oxford that brings global regulatory and legal expertise to our ambitions to transform and improve drug development pathways in order to help deliver safe and effective treatments to patients sooner. He will assume this role effective 2 January 2027.

Look Beyond My Skin: Your Psoriasis Could Help Us Understand Who Develops Psoriatic Arthritis

Adults with psoriasis across Europe are invited to take part in an online study aiming to identify who is at risk of developing psoriatic arthritis.

New PI Marie Pust aims to bring microbiome research closer to patients

We welcome Marie-Madlen Pust, who has joined the Kennedy Institute as a new Principal Investigator. Marie will establish a research group combining computational biology with targeted experimental microbiology to identify microbial drivers of chronic inflammatory disease that can be monitored (diagnostic potential) or modified (therapeutic potential).

Oxford EMCRF starts pioneering engineered nTreg trial for severe autoimmune disease

The Oxford Experimental Medicine Clinical Research Facility (EMCRF) has recruited its first patients into the CHILL trial, an early-phase study of an innovative cell therapy for severe autoimmune disease.